Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy
- Animal Testing: OK or Not? // New Moon Girls;Jul/Aug2012, Vol. 19 Issue 6, p10
The article presents views from several girls, 10 to 13 years old, whether animal testing of products must be conducted even if it is to evaluate their safety including one that suggests to start testing in simple animals and one which contends the concept as animals have the right to live.
- Clinical pharmacology. Barber, H.E.; Petrie, J.C. // British Medical Journal (Clinical Research Edition);3/7/1981, Vol. 282 Issue 6266, p809
Focuses on the principles of drug elimination by the liver and the kidneys. Reason for the occurence of drug elimination in a constant rate; Influence of patient factor to drug clearance; Example of drug following zero-order elimination kinetics.
- Factors affecting negative Common Drug Review recommendations in Canada. // PharmacoEconomics & Outcomes News;3/3/2012, Issue 648, p2
The article reports on a study published in "PharmacoEconomics" which identified the association of clinical uncertainty and price considerations with negative Common Drug Review (CDR) recommendations in Canada.
- Boning Up. Bufalino, Jamie // GQ: Gentlemen's Quarterly;Feb2004, Vol. 74 Issue 2, p68
Provides information on the pharmacological characteristics of various types of treatments for erectile dysfunction. Mechanism underlying the action of Levitra; Potential side effects of Uprima; Advantage of Cialis over Viagra.
- Orphan Drug Conundrum. Houlton, Sarah // Pharmaceutical Executive;Feb2003, Vol. 23 Issue 2, p34
Reports on the orphan drug policy established by the European Medicines Evaluation Agency in Europe. Assistance of pharmaceutical companies throughout the market authorization procedure; Classification of rare diseases; Involvement of patient groups and scientific community in providing data...
- Companies 'supressed' negative research into child drugs. // Ecologist;Jun2004, Vol. 34 Issue 5, p8
Reports on the suppression of negative results in child drugs trials by pharmaceutical companies. Contents of leaked memo from pharmaceutical company GlaxoSmithKline proving the allegations of data suppression; Percentage of negative reports on cancer drug trials based on a review of previous...
- Blinatumomab Gets 100% Response Rate Before MTD. Breindl, Anette // BioWorld International;8/20/2008, Vol. 13 Issue 34, p1
The article discusses research on the experimental drug blinatumomab for the treatment of non-Hodgkin's lymphoma. It references a study by Patrick Baeuerle and colleagues, published in the August 15, 2008, issue of "Science." In a Phase I trial of blinatumomab, which tested the BiTE antibody as...
- US court rules to allow experimental drugs for dying patients. Waltz, Emily // Nature Medicine;Jun2006, Vol. 12 Issue 6, p596
The article reports that a U.S. federal appeals court has ruled that people dying from a terminal illness have the right to buy experimental drugs from companies before the Food and Drug Administration has approved them. The ruling could bring hope to people desparately trying to extend their...
- CATIE CUtLASS: can we handle the truth? Lewis, Shôn; Lieberman, Jeffrey // British Journal of Psychiatry;Mar2008, Vol. 192 Issue 3, p161
Two large, non-commercial clinical trials comparing first- and second-generation antipsychotic drugs for people with chronic schizophrenia in the US and UK have shown unexpected results. In general, the newer drugs were no more effective or better tolerated than the older drugs. Clozapine...